Welcome to our dedicated page for Tonix Pharmaceut SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tonix Pharmaceuticals Holding Corp. (TNXP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tonix is a Nevada corporation with common stock listed on The Nasdaq Capital Market under the symbol TNXP, and it uses Forms 8-K, 10-Q, 10-K and registration statements to report material events, financial results and securities offerings related to its commercial-stage biotechnology business.
For Tonix, current and prospective shareholders often focus on filings that explain the commercialization of its FDA-approved fibromyalgia medicine TONMYA, net product revenue from its acute migraine therapies Zembrace SymTouch and Tosymra, and the funding of its development portfolio in CNS disorders, immunology, rare disease and infectious disease. Form 8-K reports detail events such as FDA IND clearance for TNX-102 SL in major depressive disorder, licensing of TNX-4900 for chronic neuropathic pain, collaborations on TNX-1500 for kidney transplant rejection, and capital markets activities including amendments to sales agreements, registered direct offerings and share repurchase authorizations.
On this page, you can review quarterly reports (Form 10-Q) and annual reports (Form 10-K) for Tonix’s consolidated financial statements, risk factor discussions and descriptions of its product pipeline. Current reports on Form 8-K highlight specific milestones, while shelf registration statements and prospectus supplements describe the terms of equity offerings used to finance commercialization and clinical development. Insider transaction reports on Form 4, when available, help investors see how Tonix officers and directors are trading the company’s stock.
Stock Titan enhances these TNXP filings with AI-powered summaries that highlight key points, such as changes in cash runway, material agreements, clinical development plans and securities issuance. Real-time updates from EDGAR mean new Tonix filings appear promptly, while AI-generated explanations can save time for readers who want to understand the implications of lengthy documents like 10-Ks, 10-Qs or complex 8-K exhibits without reading every page.
Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman bought 15,000 shares of common stock in an open-market transaction at $14.89 per share through an IRA account.
After this purchase, he held 15,001 shares indirectly via the IRA, 4,005 shares directly, and 1 share indirectly through Lederman & Co., where he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. changed its independent auditor, dismissing EisnerAmper LLP and appointing PricewaterhouseCoopers LLP for the 2026 audit, with Audit Committee approval. The company states the dismissal was not related to disagreements over accounting, disclosure, or audit scope.
EisnerAmper’s reports for 2024 and 2025 were clean except for an explanatory paragraph highlighting continuing losses and negative operating cash flows that raised substantial doubt about Tonix’s ability to continue as a going concern. Previously disclosed material weaknesses in internal control over financial reporting were remediated by year-end 2024 and did not require financial statement restatements.
Tonix Pharmaceuticals reported fourth quarter and full year 2025 results, highlighted by the November 17 U.S. launch of TONMYA for fibromyalgia. Net product revenue for 2025 was about
Cash and cash equivalents were approximately
Fourth quarter 2025 net product revenue was roughly
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company focused on central nervous system disorders, immunology, infectious diseases, and rare diseases. In August 2025 it received FDA approval for TONMYA, a bedtime, non-opioid sublingual cyclobenzaprine tablet for fibromyalgia in adults, and launched it in November 2025.
The company also markets two acute migraine products, Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray), and is advancing a broad pipeline including TNX‑102 SL for major depressive disorder and acute stress disorder, TNX‑4800 for Lyme disease prophylaxis, TNX‑1500 for kidney transplant rejection and autoimmune conditions, TNX‑1300 for cocaine intoxication, TNX‑1900 and TNX‑2900 for oxytocin‑based CNS and rare disease indications, TNX‑801 as a live‑virus smallpox/mpox vaccine candidate, and TNX‑4200 and TNX‑4900 for antiviral and neuropathic pain indications.
Tonix Pharmaceuticals Holding Corp. reported new post hoc Phase 3 data for TONMYA (cyclobenzaprine HCl sublingual tablets), its FDA‑approved fibromyalgia treatment, presented at the 8th International Congress on Controversies in Fibromyalgia.
In the 14‑week RESILIENT study of 457 adults, TONMYA produced rapid pain relief versus placebo as early as Day 2, with statistically significant pain reductions each week through Week 14 and a least‑squares mean treatment difference of -0.65 on numeric rating scale pain scores. All key secondary endpoints favored TONMYA, and discontinuations due to adverse events were 6.1% versus 3.5% with placebo, mainly mild, transient oral cavity reactions.
A pooled analysis of 959 participants from the RELIEF and RESILIENT trials showed a number needed to treat of 7 for ≥30% pain reduction and a number needed to harm of 26 for discontinuation due to adverse events, yielding a likelihood to be helped or harmed of 3.7. The company highlights TONMYA as the first new prescription medicine for fibromyalgia in more than 15 years and provides extensive prescribing, safety, and use‑in‑population information.
Tonix Pharmaceuticals Holding Corp. announced that Nasdaq approved transferring its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the new tier expected to begin at the open of market on March 3, 2026 under the ticker “TNXP.”
The Nasdaq Global Select Market is the highest of Nasdaq’s three tiers, designed for companies that meet higher financial, liquidity and corporate governance requirements. Tonix notes that the uplisting reflects its compliance with these standards and may enhance visibility with institutional investors, improve trading liquidity and broaden market recognition.
Tonix Pharmaceuticals Holding Corp. reported that Chief Operating Officer Jessica Edgar Morris received two grants of stock options. One grant covers 39,012 stock options and the other covers 39,011 stock options, both awarded at an exercise price of $0.00 per share.
According to the vesting terms, one-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan.
SAENGER BRADLEY reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. reported that Chief Financial Officer Bradley Saenger received two grants of stock options on February 24, 2026, covering 39,012 and 39,011 underlying shares. The options were issued under the company’s Amended and Restated 2020 Stock Incentive Plan.
According to the vesting terms, one-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments of 1/48 each month over the following 36 months. These awards increase the CFO’s directly held derivative securities in the company.
SULLIVAN GREGORY M reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. Chief Medical Officer Gregory M. Sullivan reported receiving two grants of stock options covering 39,012 and 39,011 shares on